MAK Capital

MARAbio is a biotechnology firm focused on detecting and preventing severe forms of autism. The company specializes in maternal autoantibody-related autism testing, which aims to determine the risk of autism spectrum disorder (ASD). MARAbio's licensed technology identifies a unique cluster of antibodies in mothers that target proteins in the developing brain of children later diagnosed with ASD. This early identification allows for the initiation of beneficial behavioral therapies if developmental delays are observed in children.

Noveome Biotherapeutics, Inc. is a clinical-stage biotherapeutics company based in Pittsburgh, Pennsylvania, focused on developing innovative therapies for the regenerative repair of inflamed or damaged tissues. Founded in 2000 and formerly known as Stemnion, Inc., the company specializes in paracrine signaling, disrupted signaling, and secretome solutions. Its lead product, ST266, is designed to modulate inflammation, enhance wound healing, promote bone restoration, restore nerve function, and regenerate cells. Noveome's products leverage a range of biologic components at physiological concentrations that work synergistically to provide anti-inflammatory, neuroprotective, anti-apoptotic, and vascular integrity-preserving effects, thereby assisting healthcare providers in addressing complex diseases.

Trailhead Biosystems specializes in developing cell therapy solutions by integrating developmental biology and cell therapeutics with advanced hardware and software services. The company utilizes computerized experimental design and analysis to optimize process-specific parameters, assisting customers in the development of cell therapies. This approach helps healthcare clients reduce the number of experiments and time typically required for optimizing multiple variables, thereby streamlining the therapeutic production process.